On this page
GREM1
gremlin 1, DAN family BMP antagonist
GREM1, or gremlin 1, is a gene that plays a key role in regulating cell growth and development by inhibiting certain signalling pathways, and is associated with an increased risk of inherited colorectal cancer. The GREM1 gene provides instructions for making a protein involved in various developmental processes and tissue remodelling.
GREM1 is located on the long (q) arm of chromosome 15, at band 15q13.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 15 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The GREM1 gene, also known as gremlin 1, is crucial for normal embryonic development and tissue maintenance in adults. It encodes a protein that acts as an antagonist to bone morphogenetic proteins (BMPs), which are a group of growth factors that regulate cell proliferation, differentiation, and apoptosis (programmed cell death).
When GREM1 function is altered, it can disrupt the delicate balance of cell signalling pathways. This disruption has been implicated in various disease processes, including the development and progression of certain cancers. Specifically, variations within the GREM1 gene are associated with an increased risk for inherited forms of colorectal cancer, highlighting its significance in human health and disease.
What the gene does
The GREM1 gene encodes the gremlin 1 protein, which primarily functions as a secreted antagonist to bone morphogenetic proteins (BMPs). BMPs belong to the transforming growth factor-beta (TGF-beta) superfamily and are involved in regulating cell growth, differentiation, and tissue morphogenesis. Gremlin 1 binds directly to BMPs, preventing them from interacting with their cell surface receptors, thereby inhibiting BMP signalling.
This inhibitory action is critical for precise spatial and temporal control over developmental processes, including limb development, kidney formation, and lung branching. In adults, GREM1 continues to play a role in tissue homeostasis and repair. Its involvement in regulating cell proliferation and differentiation means that dysregulation of GREM1 activity can contribute to abnormal cell growth, a hallmark of cancer. Specifically, altered GREM1 expression or function can lead to uncontrolled cell proliferation in the gastrointestinal tract, contributing to colorectal cancer development.
Video: Genetics 101
Chromosome location
The GREM1 gene is situated on chromosome 15 at position 15q13.3. This means that it is located on the long arm (q) of chromosome 15, within region 1, band 3, and sub-band 3. This specific chromosomal address helps geneticists locate and study the gene within the human genome. The precise location is important for understanding potential genomic rearrangements or mutations that could affect GREM1 function and its associated health implications.
Protein structure
The GREM1 protein consists of 184 amino acids, and its structure includes distinct functional regions. One notable segment is the Disordered region, spanning amino acids 24-77. This region is typically flexible and lacks a fixed three-dimensional structure, which can be important for protein-protein interactions and signalling. The protein also contains a C-terminal cysteine knot (CTCK) domain, located from amino acids 94-184. The CTCK domain is characteristic of antagonists like gremlin and is responsible for binding to and antagonising Bone Morphogenetic Proteins (BMPs), thereby inhibiting their signalling pathways. This domain architecture is critical for GREM1's ability to regulate cell development and growth.
Key variants
Genetic variants within the GREM1 gene can have significant impacts on its function and the biological pathways it regulates. These variants may include small changes like single nucleotide polymorphisms (SNPs), or larger alterations such as insertions, deletions, or duplications. The effect of a variant depends on its location within the gene and how it alters the resulting protein. Some variants might lead to a non-functional protein, while others could reduce its activity or alter its stability. Such changes can disrupt the delicate balance of BMP signalling, potentially leading to increased cellular proliferation and an elevated risk for certain medical conditions.
Sample of pathogenic variants
1 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
g.(?_32971947)_(33004759_?)dup | - | Pathogenic | ★☆☆☆ | Familial colorectal cancer |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variations in the GREM1 gene have been associated with a predisposition to certain health conditions, particularly within the digestive system. Most notably, GREM1 is implicated in an increased risk for colorectal cancer. This includes hereditary forms where specific genetic changes can substantially elevate an individual's lifetime risk of developing this type of cancer. The gene's role in regulating cell growth pathways suggests a mechanism by which its dysregulation contributes to uncontrolled cell proliferation characteristic of cancer.
Inheritance pattern
Conditions caused by pathogenic GREM1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the GREM1 gene is recognised within national genomic testing guidelines for its association with specific inherited conditions. It is included on the Inherited polyposis and early onset colorectal cancer - germline testing panel (R211) within NHS Genomic Medicine Service pathways. This indicates that GREM1 is considered a gene of clinical significance for individuals undergoing genetic testing for these conditions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research suggests that general healthy lifestyle choices may play a role in managing overall cancer risk, including for conditions associated with GREM1 alterations. Maintaining a balanced diet rich in fruits, vegetables, and fibre, along with regular physical activity, is generally recommended for population-level health. Limiting consumption of processed meats and alcohol, and avoiding smoking, are also commonly advised. While these lifestyle factors do not alter an individual's genetic predisposition, they can contribute to overall wellbeing and may influence other pathways involved in cancer development.
Supplement considerations
There is currently no conclusive scientific evidence to suggest that specific dietary supplements can prevent or treat conditions associated with GREM1 gene variations. While certain vitamins or minerals are often promoted for their general health benefits, individuals should approach such claims with caution. It is always important to discuss any interest in taking supplements with a healthcare provider, especially if there is a known genetic predisposition to a medical condition. A healthcare professional can provide personalised advice based on an individual's specific health needs and medical history.
Frequently asked questions
What is the primary function of the GREM1 gene?
The GREM1 gene provides instructions for making the gremlin 1 protein, which acts as an antagonist to bone morphogenetic proteins (BMPs). By inhibiting BMP signalling, it plays a critical role in regulating cell proliferation, differentiation, and tissue development.
How is GREM1 associated with colorectal cancer?
Variations in the GREM1 gene are linked to an increased risk of inherited colorectal cancer. Its role in controlling cell growth pathways means that alterations can lead to unchecked cell proliferation in the colon, contributing to cancer development.
Is GREM1 testing available in the UK?
Yes, GREM1 is included in the Inherited polyposis and early onset colorectal cancer - germline testing panel (R211) as part of the NHS Genomic Medicine Service pathways, indicating its clinical significance for these conditions.
What kind of protein does GREM1 produce?
The GREM1 gene produces a protein called gremlin 1, which is a secreted protein. It contains a characteristic C-terminal cysteine knot (CTCK) domain that is responsible for binding and inhibiting BMPs.
Can lifestyle changes prevent GREM1-associated conditions?
While lifestyle changes cannot alter genetic predispositions, adopting a healthy lifestyle, including a balanced diet and regular exercise, is generally recommended for overall health and may influence broader cancer risk factors. Always consult a healthcare provider for personalised advice.